DK2473487T3 - QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS - Google Patents

QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS Download PDF

Info

Publication number
DK2473487T3
DK2473487T3 DK10754824.0T DK10754824T DK2473487T3 DK 2473487 T3 DK2473487 T3 DK 2473487T3 DK 10754824 T DK10754824 T DK 10754824T DK 2473487 T3 DK2473487 T3 DK 2473487T3
Authority
DK
Denmark
Prior art keywords
alkyl
heteroaryl
heterocyclyl
independently selected
membered
Prior art date
Application number
DK10754824.0T
Other languages
Danish (da)
English (en)
Inventor
Prashantha Gunaga
Abhisek Banerjee
Ashokkumar Adisechan
James A Johnson
John Lloyd
Heather Finlay
Ji Jiang
James Neels
Naveen Kumar Dhondi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2473487T3 publication Critical patent/DK2473487T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Catching Or Destruction (AREA)
DK10754824.0T 2009-09-03 2010-09-01 QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS DK2473487T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23945209P 2009-09-03 2009-09-03
PCT/US2010/047430 WO2011028741A1 (en) 2009-09-03 2010-09-01 Quinazolines as potassium ion channel inhibitors

Publications (1)

Publication Number Publication Date
DK2473487T3 true DK2473487T3 (en) 2017-02-06

Family

ID=42942118

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10754824.0T DK2473487T3 (en) 2009-09-03 2010-09-01 QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS
DK19186129.3T DK3575288T3 (da) 2009-09-03 2010-09-01 Quinazoliner som kaliumionkanalinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19186129.3T DK3575288T3 (da) 2009-09-03 2010-09-01 Quinazoliner som kaliumionkanalinhibitorer

Country Status (32)

Country Link
US (9) US8575184B2 (enExample)
EP (3) EP3124475B1 (enExample)
JP (2) JP5643312B2 (enExample)
KR (1) KR101698631B1 (enExample)
CN (1) CN102753535B (enExample)
AR (1) AR078326A1 (enExample)
AU (1) AU2010289641B2 (enExample)
BR (1) BR112012008330B1 (enExample)
CA (1) CA2772642C (enExample)
CL (1) CL2012000583A1 (enExample)
CO (1) CO6511220A2 (enExample)
CY (2) CY1118488T1 (enExample)
DK (2) DK2473487T3 (enExample)
EA (1) EA021113B1 (enExample)
ES (3) ES2750598T3 (enExample)
HR (2) HRP20161669T1 (enExample)
HU (2) HUE057433T2 (enExample)
IL (1) IL218169A (enExample)
LT (2) LT3575288T (enExample)
MX (1) MX2012002099A (enExample)
MY (1) MY160243A (enExample)
NZ (1) NZ598516A (enExample)
PE (1) PE20121153A1 (enExample)
PL (2) PL3575288T3 (enExample)
PT (2) PT2473487T (enExample)
SG (1) SG178592A1 (enExample)
SI (2) SI3575288T1 (enExample)
SM (3) SMT202100717T1 (enExample)
TN (1) TN2012000063A1 (enExample)
TW (1) TWI488851B (enExample)
WO (1) WO2011028741A1 (enExample)
ZA (1) ZA201202383B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH068949B2 (ja) 1985-09-20 1994-02-02 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料
PT2473487T (pt) * 2009-09-03 2017-01-04 Bristol Myers Squibb Co Quinazolinas como inibidores dos canais iónicos de potássio
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
US20140315886A1 (en) * 2011-06-29 2014-10-23 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
WO2013143319A1 (zh) * 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
WO2013188254A1 (en) * 2012-06-11 2013-12-19 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
EP2963019B1 (en) 2013-02-28 2020-08-12 Takeda Pharmaceutical Company Limited Method for producing pyridine-3-sulfonyl chloride
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのイソキノリン
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143607A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
CN105636955B (zh) * 2013-10-17 2018-01-12 住友化学株式会社 四唑啉酮化合物及其用途
CA2951790C (en) 2014-06-10 2022-05-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
KR20170013994A (ko) 2014-06-10 2017-02-07 우베 고산 가부시키가이샤 N-치환 술폰아미드 화합물 및 그의 제조 방법
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
WO2016090299A1 (en) 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
US20180338980A1 (en) * 2015-06-10 2018-11-29 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
CN109415321B (zh) 2016-05-03 2022-06-17 拜耳制药股份公司 芳族磺酰胺衍生物
CN106432067B (zh) * 2016-09-18 2019-04-19 北京天弘天达医药科技有限公司 一种3-吡啶磺酰氯的绿色化学合成方法
SG11202003565PA (en) * 2017-10-29 2020-05-28 Bayer Ag Aromatic sulfonamide derivatives for the treatment of ischemic stroke
JP2021522181A (ja) * 2018-04-20 2021-08-30 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としてのヘテロアリール−トリアゾール化合物及びヘテロアリール−テトラゾール化合物
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN116323623B (zh) 2020-09-18 2025-09-26 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
EP4514354A1 (en) * 2022-04-28 2025-03-05 University of Miami Compounds for proliferative disorders
CN119894893A (zh) 2022-09-16 2025-04-25 拜耳公司 用于治疗癌症的砜取代的吡啶并[3,4-d]嘧啶衍生物
EP4602049A1 (en) 2022-10-13 2025-08-20 Bayer Aktiengesellschaft Sos1 inhibitors
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843791A (en) 1973-01-11 1974-10-22 Pfizer Method of killing insects with quinazolinones and quinazoline-thiones
ATE156120T1 (de) 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
AU664337B2 (en) 1993-06-17 1995-11-09 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
US6248771B1 (en) 1997-03-05 2001-06-19 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1391562A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
US6506762B1 (en) * 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
WO2001064646A2 (en) 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
CN1474815A (zh) 2000-09-20 2004-02-11 Ĭ��ר���ɷ����޹�˾ 4-氨基-喹唑啉
WO2002024666A2 (en) 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
WO2002062767A1 (en) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2004030671A2 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
AU2003292435A1 (en) 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
AU2003290279A1 (en) 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
ZA200507979B (en) * 2003-03-03 2007-03-28 Vertex Pharma Inc Quinazolines useful as modulators of ion channels
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US20070010671A1 (en) 2003-03-31 2007-01-11 Yoshinori Sekiguchi Novel quinazoline derivatives and methods of treatment related to the use thereof
MXPA05013549A (es) 2003-06-11 2006-04-05 Xention Discovery Ltd Derivados de tienopirimidina como inhibidores del canal de potasio.
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
JP5129957B2 (ja) 2003-07-03 2013-01-30 ミリアド ジェネティクス， インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン
US7906521B2 (en) * 2003-09-23 2011-03-15 Merck Sharp & Dohme Corp. Quinazoline potassium channel inhibitors
JP2007510642A (ja) 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
JPWO2005087749A1 (ja) 2004-03-15 2007-08-09 協和醗酵工業株式会社 ２−アミノキナゾリン誘導体
MXPA06014256A (es) 2004-06-10 2007-03-12 Xention Discovery Ltd Compuestos de furano-pirimidina efectivos como inhibidores del canal de potasio.
US20060014705A1 (en) 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
AU2005269974A1 (en) 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
CN101146549A (zh) 2005-02-18 2008-03-19 诺华疫苗和诊断公司 抗血管新生剂与阿地白介素
NZ556248A (en) 2005-03-14 2010-06-25 Neurosearch As Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
WO2006105063A1 (en) 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
EP1901744A2 (en) 2005-06-28 2008-03-26 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
CN101360738A (zh) 2005-12-21 2009-02-04 佩因赛普托药物公司 调节门控离子通道的组合物和方法
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
EP2061764B1 (en) 2006-08-22 2014-07-02 Technion Research & Development Foundation LTD. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009006141A2 (en) 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101575333B (zh) 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
US20110098305A1 (en) 2008-05-21 2011-04-28 Jonathan Bayldon Baell Arylsulfonamide compounds, compositions and methods of use
PT2473487T (pt) * 2009-09-03 2017-01-04 Bristol Myers Squibb Co Quinazolinas como inibidores dos canais iónicos de potássio
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos

Also Published As

Publication number Publication date
EP2473487B1 (en) 2016-10-26
HUE032983T2 (en) 2017-11-28
AU2010289641B2 (en) 2015-05-07
US9822096B2 (en) 2017-11-21
LT2473487T (lt) 2017-01-10
US20250230144A1 (en) 2025-07-17
SI3575288T1 (sl) 2022-01-31
CY1125021T1 (el) 2023-03-24
SMT201700026T1 (it) 2017-03-08
SI2473487T1 (sl) 2017-02-28
US20180030034A1 (en) 2018-02-01
BR112012008330A2 (pt) 2021-02-17
HRP20161669T1 (hr) 2017-02-24
KR101698631B1 (ko) 2017-01-20
US10214511B2 (en) 2019-02-26
ES2900504T3 (es) 2022-03-17
EA021113B1 (ru) 2015-04-30
PL2473487T3 (pl) 2017-07-31
SG178592A1 (en) 2012-04-27
BR112012008330B1 (pt) 2022-03-22
SMT202100717T1 (it) 2022-01-10
EP3575288B1 (en) 2021-10-27
US20160362396A1 (en) 2016-12-15
US11008306B2 (en) 2021-05-18
CN102753535A (zh) 2012-10-24
LT3575288T (lt) 2021-12-10
EA201270378A1 (ru) 2012-07-30
HRP20211973T1 (hr) 2022-03-18
KR20120125978A (ko) 2012-11-19
TWI488851B (zh) 2015-06-21
US20140031345A1 (en) 2014-01-30
JP5950978B2 (ja) 2016-07-13
CY1118488T1 (el) 2017-07-12
CO6511220A2 (es) 2012-08-31
US20190144426A1 (en) 2019-05-16
AR078326A1 (es) 2011-11-02
HUE057433T2 (hu) 2022-05-28
ES2750598T3 (es) 2020-03-26
JP2015057410A (ja) 2015-03-26
US8575184B2 (en) 2013-11-05
JP2013503875A (ja) 2013-02-04
US10676460B2 (en) 2020-06-09
IL218169A0 (en) 2012-07-31
JP5643312B2 (ja) 2014-12-17
WO2011028741A1 (en) 2011-03-10
EP3575288A1 (en) 2019-12-04
CL2012000583A1 (es) 2012-08-31
EP2473487A1 (en) 2012-07-11
DK3575288T3 (da) 2021-12-20
IL218169A (en) 2015-11-30
US20200255407A1 (en) 2020-08-13
US9458114B2 (en) 2016-10-04
EP3124475B1 (en) 2019-08-07
ES2609335T3 (es) 2017-04-19
MX2012002099A (es) 2012-04-11
SMT201700026B (it) 2017-03-08
CA2772642A1 (en) 2011-03-10
CN102753535B (zh) 2015-03-25
CA2772642C (en) 2017-08-29
PT3575288T (pt) 2021-12-09
US20230322726A1 (en) 2023-10-12
PL3575288T3 (pl) 2022-01-24
EP3124475A1 (en) 2017-02-01
NZ598516A (en) 2013-02-22
PE20121153A1 (es) 2012-08-27
US20220324836A1 (en) 2022-10-13
MY160243A (en) 2017-02-28
TW201113267A (en) 2011-04-16
US20120232068A1 (en) 2012-09-13
TN2012000063A1 (en) 2013-09-19
ZA201202383B (en) 2013-09-25
PT2473487T (pt) 2017-01-04
AU2010289641A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
DK2473487T3 (en) QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS
US9242966B2 (en) Phthalazines as potassium ion channel inhibitors
US9458133B2 (en) Isoquinolines as potassium ion channel inhibitors
EP2970295A1 (en) Pyrrolopyridazines as potassium ion channel inhibitors
HK40018229A (en) Quinazolines as potassium ion channel inhibitors
HK40018229B (en) Quinazolines as potassium ion channel inhibitors